Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction.
OBJECTIVE
To investigate the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction.


METHODS
One hundred and sixty-two consecutive patients who had suffered from adhesive intestinal obstruction without clinical evidence of strangulation or gangrene were randomised into two groups, a control group (treated conservatively, n=82) and a contrast group (treated with combined administration of octreotide and methylglucamine diatrizoate, n=80). A laparotomy was performed in both the two groups if symptoms of strangulation developed or the obstruction did not resolve spontaneously after 72 h.


RESULTS
Statistically significant rapid reduction in pain score, lower amount of nasogastric drainage, shorter hospital stay, lower operative rate and lower postoperative morbidity were observed in the contrast group. Among the non-operative patients, earlier passage of stool and gas, earlier first oral intake and shorter duration of nasogastric tube placement were significantly more frequently observed in the contrast group. No difference in the rate of readmission was found between the two groups.


CONCLUSIONS
Combined administration of octreotide and methylglucamine diatrizoate accelerates resolution of small bowel obstruction by a specific therapeutic effect and is safe for the older persons.
Zhang
Y
Y
Department of Hepatobiliary Surgery, The First Hospital of Xi'an Jiaotong University, 1 Jiankang Street, 710061 Xi'an, China.
Gao
Y
Y
Ma
Q
Q
Dang
C
C
Wei
W
W
De Antoni
F
F
Rocci
R
R
Chen
W
W
D000368:Aged; D000369:Aged, 80 and over; D003287:Contrast Media / Q000008:administration & dosage*; D003974:Diatrizoate Meglumine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007415:Intestinal Obstruction / Q000188:drug therapy*; D007421:Intestine, Small; D007441:Intubation, Gastrointestinal; D007902:Length of Stay; D008297:Male; D015282:Octreotide / Q000008:administration & dosage*; D010147:Pain Measurement; D010359:Patient Readmission; D011446:Prospective Studies; D000267:Tissue Adhesions
D003287:Contrast Media; D005765:Gastrointestinal Agents; D003974:Diatrizoate Meglumine; D015282:Octreotide